Evidence map›Paper›PMID 41694576›Full record

ReviewInternational journal of biological sciences2026

Reprogrammed Fibrotic Niche Fuels Lung Cancer Initiation and Reciprocal Remodeling.

Zhufeng Hu, Wu Dan, Mengran Xi, Zhengyuan Fang, Kunlun Feng, Jie Mei, Zhang Ting, Baojun Liu, Zhiwen Luo

Abstract readReview
In one paragraph

Review in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhufeng HuDepartment of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.
Wu DanDepartment of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.
Mengran XiCity University of Hong Kong, China.
Zhengyuan FangDepartment of Gastrointestinal Surgery, Renji Hospital, Shanghai 200127, China.
Kunlun FengFirst Clinical College, Shandong University of Traditional Chinese Medicine, China.
Jie MeiThe First Clinical Medicine College, Nanjing Medical University, Nanjing, 211166, China.
Zhang TingDepartment of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.
Baojun LiuDepartment of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.
Zhiwen LuoDepartment of Integrative Medicine, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary Fibrosis (PF), an end-stage manifestation of interstitial lung diseases, is associated with largely unfavorable prognoses. Lung cancer (LC), a leading cause of nationally cancer-related mortality with progressively increasing incidence, exhibits pathological interconnections with PF. The chronic remodeling of the pulmonary microenvironment-including cellular components, extracellular matrix (ECM), inflammatory cytokine networks, and metabolic reprogramming-represents the core pathogenic mechanism underlying PF-LC comorbidity. This review systematically elaborates how the fibrotic microenvironment promotes malignant transformation of lung cancer via chronic inflammation, increased matrix stiffness, immunosuppressive regulation, and epigenetic modulation. Furthermore, we investigate the bidirectional crosstalk by which LC progression reciprocally modulates fibrotic processes. Finally, we integrate current clinical challenges and propose novel therapeutic strategies targeting the fibrotic microenvironment to address this lethal pathophysiological synergy.

Indexed as

Lung NeoplasmsPulmonary FibrosisAnimalsExtracellular MatrixHumansMetabolic ReprogrammingTumor Microenvironmentcancer-associated fibroblastslung cancermechanotransductionmetabolic reprogrammingmicrobiome dysbiosispulmonary fibrotic microenvironment

Identifiers

PMID41694576
PMCPMC12905585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.